TABLE 2.
Point dose estimates of telavancin required to attain different pharmacodynamic endpoints against gram-positive bacterial strains in the MNT model
| Organism | 24-h growth (log CFU/g)a | Doses (mg/kg) of telavancin required to attainb:
|
||||
|---|---|---|---|---|---|---|
| ED50 | EDstasis | ED1-log kill | ED2-log kill | ED3-log kill | ||
| MRSA 33591 | 3.7 | 2.5 | 6.3 | 27.5 | — | — |
| MRSA MCJ25 | 3.3 | 3.1 | 4.4 | 8.9 | 37.1 | — |
| MRSA SFVA06 | 2.8 | 3.7 | 3.3 | 6.1 | 14.4 | — |
| MRSA MGH 10 | 4.0 | 4.4 | 8.5 | 29.5 | — | — |
| MSSA 13709 | 3.5 | 1.7 | 2.5 | 5.5 | 58.9 | — |
| MSSA KPB01 | 3.7 | 2.2 | 6.3 | 47.8 | — | — |
| MSSA KPB04 | 4.1 | 1.7 | 6.3 | 32.3 | — | — |
| MSSA MED 415 | 4.2 | 2.0 | 2.8 | 4.8 | 10.7 | 50 |
| MRSE SFVA01 | 1.0 | 1.0 | 0.7 | 1.4 | 6.7 | — |
| MSSE SU03 | 2.0 | 1.2 | 0.9 | 2.9 | 23.9 | — |
| PRSP SU2 | 2.2 | 0.5 | 0.4 | 0.6 | 1.1 | 3.5 |
| PRSP CHM11 | 3.5 | 2.9 | 3.3 | 5.4 | 10.9 | 50 |
| PSSP SU10 | 3.3 | 1.8 | 1.7 | 2.6 | 4.6 | 12.0 |
| PSSP SU07 | 4.1 | 2.0 | 2.8 | 5.2 | 12.8 | 50 |
| VREFs A256 | 2.0 | 6.6 | 50 | — | — | — |
a
Calculated as the difference between the 24-h titer in vehicle-treated animals and the pretreatment titer.
b
Refer to Materials and Methods for definition of pharmacodynamic endpoints. —, endpoint not achieved at the doses tested.